BioHorizons Tapered Short Implants

K172576 · BioHorizons Implant Systems, Inc. · DZE · Nov 22, 2017 · Dental

Device Facts

Record IDK172576
Device NameBioHorizons Tapered Short Implants
ApplicantBioHorizons Implant Systems, Inc.
Product CodeDZE · Dental
Decision DateNov 22, 2017
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 872.3640
Device ClassClass 2
AttributesTherapeutic

Intended Use

BioHorizons Tapered Short Implants are intended for use in the mandible or maxilla as an artificial root structure for single tooth replacement or for fixed bridgework and dental retention. The implants may be restored using delayed loading, or with a terminal or intermediate abutment for fixed or removable bridgework, and for overdentures.

Device Story

BioHorizons Tapered Short Implants are machined titanium alloy (ASTM F136) screw-form endosseous dental implants; available in 4.6mm and 5.8mm diameters and 6.0mm and 7.5mm lengths. Devices feature Resorbable Blast Texture (RBT) on threaded surfaces and Laser-Lok microchannels on the collar to inhibit epithelial downgrowth and promote connective tissue attachment. Used by dental clinicians in clinical settings for tooth replacement or prosthetic retention. Implants are surgically placed in the mandible or maxilla; restored via delayed loading protocols. Benefits include artificial root structure for dental restoration. Device is non-active, non-mechanical, and provided sterile via gamma radiation.

Clinical Evidence

Bench testing only. Mechanical fatigue testing performed per ISO 14801 and FDA guidance. Axial pullout testing performed per ASTM F543. Surface area and bone-to-implant contact (BIC) comparative analysis performed. Sterility validated per ANSI/AAMI/ISO 11137-1. Endotoxin testing performed per USP <85>. Shelf life validated per ASTM standards for packaging. Biocompatibility supported by historical data for ASTM F136 titanium alloy.

Technological Characteristics

Material: Ti-6Al-4V (ASTM F136). Surface: RBT (tricalcium phosphate) and Laser-Lok microchannels. Connection: Internal Hex. Sterilization: Gamma radiation (min 25 kGy). Dimensions: 4.6/5.8mm diameter, 6.0/7.5mm length. Non-active, non-mechanical.

Indications for Use

Indicated for patients requiring single tooth replacement, fixed bridgework, or dental retention in the mandible or maxilla. Suitable for use with delayed loading protocols or with terminal/intermediate abutments for fixed/removable bridgework and overdentures.

Regulatory Classification

Identification

An endosseous dental implant is a prescription device made of a material such as titanium or titanium alloy that is intended to be surgically placed in the bone of the upper or lower jaw arches to provide support for prosthetic devices, such as artificial teeth, in order to restore a patient's chewing function.

Special Controls

*Classification.* (1) Class II (special controls). The device is classified as class II if it is a root-form endosseous dental implant. The root-form endosseous dental implant is characterized by four geometrically distinct types: Basket, screw, solid cylinder, and hollow cylinder. The guidance document entitled “Class II Special Controls Guidance Document: Root-Form Endosseous Dental Implants and Endosseous Dental Implant Abutments” will serve as the special control. (See § 872.1(e) for the availability of this guidance document.)(2) *Classification.* Class II (special controls). The device is classified as class II if it is a blade-form endosseous dental implant. The special controls for this device are:(i) The design characteristics of the device must ensure that the geometry and material composition are consistent with the intended use; (ii) Mechanical performance (fatigue) testing under simulated physiological conditions to demonstrate maximum load (endurance limit) when the device is subjected to compressive and shear loads; (iii) Corrosion testing under simulated physiological conditions to demonstrate corrosion potential of each metal or alloy, couple potential for an assembled dissimilar metal implant system, and corrosion rate for an assembled dissimilar metal implant system; (iv) The device must be demonstrated to be biocompatible; (v) Sterility testing must demonstrate the sterility of the device; (vi) Performance testing to evaluate the compatibility of the device in a magnetic resonance (MR) environment; (vii) Labeling must include a clear description of the technological features, how the device should be used in patients, detailed surgical protocol and restoration procedures, relevant precautions and warnings based on the clinical use of the device, and qualifications and training requirements for device users including technicians and clinicians; (viii) Patient labeling must contain a description of how the device works, how the device is placed, how the patient needs to care for the implant, possible adverse events and how to report any complications; and (ix) Documented clinical experience must demonstrate safe and effective use and capture any adverse events observed during clinical use.

Predicate Devices

Reference Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logos of the Department of Health & Human Services and the Food and Drug Administration (FDA). The Department of Health & Human Services logo is on the left, and the FDA logo is on the right. The FDA logo includes the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text. BioHorizons Implant Systems, Inc. Michael Davis Director, Regulatory Affairs 2300 Riverchase Center Birmingham, Alabama 35244 Re: K172576 Trade/Device Name: BioHorizons Tapered Short Implants Regulation Number: 21 CFR 872.3640 Regulation Name: Endosseous Dental Implant Regulatory Class: Class II Product Code: DZE Dated: August 25, 2017 Received: August 28, 2017 Dear Michael Davis: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); November 22, 2017 {1}------------------------------------------------ and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely, Mary S. Runner -S forTina Kiang, Ph.D. Acting Director Division of Anesthesiology, General Hospital, Respiratory, Infection Control, and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K172576 #### Device Name BioHorizons Tapered Short Implants #### Indications for Use (Describe) BioHorizons Tapered Short Implants are intended for use in the mandible or maxilla as an artificial root structure for single tooth replacement or for fixed bridgework and dental retention. The implants may be restored using delayed loading, or with a terminal or intermediate abutment for fixed or removable bridgework, and for overdentures. | Type of Use (Select one or both, as applicable) | | |------------------------------------------------------------|-----------------------------------------------------------| | <span></span> Prescription Use (Part 21 CFR 801 Subpart D) | <span></span> Over-The-Counter Use (21 CFR 801 Subpart C) | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ### 510(k) Summary 21 CFR 807.92 #### Submitter's Name & Address | Manufacturer: | BioHorizons Implant Systems, Inc.<br>2300 Riverchase Center<br>Birmingham, AL 35244<br>Phone (205) 967-7880<br>Fax (205) 870-0304 | |-------------------|-----------------------------------------------------------------------------------------------------------------------------------| | Official contact: | Michael Davis, Director, Regulatory Affairs | | Date prepared: | November 21, 2017 | ### Name of the Device | Trade Name: | BioHorizons Tapered Short Implants | |------------------------|------------------------------------| | Common or Usual Name: | Screw-type dental implant | | Classification Name: | Endosseous dental implant | | Classification Number: | Class II (21 CFR 872.3640) | | Primary Product Code : | DZE | ## Predicate Devices Primary Predicate Device: 1. K121787, BioHorizons Tapered Internal Plus Implants, September 5, 2012. Reference Predicate Devices: - 1. K150571, Biomet 3i T3 Short Implants, November 20, 2015. - 2. K073368, Bicon, LLC The Bicon 5.0 x 5.0mm and 6.0 x 5.0mm Dental Implant, October 10. 2008. - 3. K050712, Bicon, LLC 4.5 x 6.0mm and 6.0 x 6.0mm Dental Implant, May 16, 2005. ### Device Description The BioHorizons Tapered Short Implants are machined titanium, screw-form endosseous dental implants supplied in 4.6mm and 5.8mm diameters. The 4.6mm diameter implant includes a 3.5mm prosthetic platform, while the 5.8mm diameter implant includes a 4.5mm prosthetic platform. The implants are provided in 6.0mm and 7.5mm lengths across both diameters. Implant material is titanium alloy as specified in ASTM F136 Standard Specification for Wrought Titanium-6Aluminum-4Vanadium ELI (Extra Low Interstitial) Allov (UNS R56401) for Surgical Implant Applications. The devices are further processed by roughening the threaded surface with Resorbable Blast Texture (RBT) media (tricalcium phosphate) and by micro-machining grooves, known as Laser-Lok® microchannels, on the implant collar. The product is packaged using materials known in the industry to be appropriate for medical device packaging and is provided with a minimum sterility assurance level of 10°, validated in compliance with ANSI/AAMI/ISO 11137-1 Sterilization of healthcare products -- Radiation -- Part 1: Requirements for development, validation and routine control of a sterilization process for medical devices. ### Indications for Use BioHorizons Tapered Short Implants are intended for use in the mandible or maxilla as an artificial root structure for single tooth replacement or for fixed bridgework and dental retention. The implants may be restored using delayed loading, or with a terminal or intermediate abutment for fixed or removable bridgework, and for overdentures. {4}------------------------------------------------ The main difference between the Indications for Use statements between the subject device and the primary predicate device is with regard to immediate versus delayed loading protocols. The subject device is intended for delayed loading, whereas the primary predicate device was cleared for immediate restoration 1) with a temporary prosthesis that is not in functional occlusion, or 2) when splinted together for multiple tooth replacement, or when stabilized with an overdenture supported by multiple implants. Both devices are indicated for fixed or removeable bridgework and for overdentures. No other substantive differences exist between the Indications for Use statements between the subject and primary predicate devices. # Technological Characteristics The fundamental scientific technology of the BioHorizons Tapered Short endosseous dental implant devices subject to this 510(k) is substantially equivalent to the referenced primary predicate device. The threaded portion of the implants is RBT-blasted, and Laser-Lok microchannels are applied to the implant collar. Laser-Lok is a surface feature in which patterns of micro-machined grooves are applied to the collar of a dental implant, providing a roughened surface to establish a physical, connective tissue attachment. This tissue connection: - 1) is functionally oriented, - 2) inhibits epithelial cell downgrowth, and - 3) enables crestal bone adjacent to the implant to attach and be retained. The preceding claims 1-3 are supported in the published literature by Nevins et al. Human Histologic Evidence of a Connective Tissue Attachment to a Dental Implant, International Journal of Periodontics & Restorative Dentistry 2008; 28:111-121. All materials, suppliers, processing, packaging and sterilization methods remain the same as for the primary predicate device, BioHorizons Tapered Internal Plus Implants (K121787). The Laser-Lok feature is substantially equivalent to that cleared for the BioHorizons Tapered Internal Plus Implants. The BioHorizons Tapered Short Implants are substantially equivalent to the features of the predicate implant devices because of the similarities in design, materials and intended use. Refer to Table 1, Summary Table of Substantial Equivalence, immediately following. ### Summary of Testing Mechanical fatigue testing of the worst-case (smallest prosthetic platform/smallest implant body diameter combined with the shortest implant length) 4.6mm x 6.0mm Tapered Short Implant was performed in accordance with the Class II Special Controls Guidance Document: Root-form Endosseous Dental Implants and Endosseous Dental Implant Abutments. May 12, 2004 and ISO 14801. The load-bearing features of the implant-abutment connection were tested in conjunction with angled prosthetic abutments representative of the worst-case scenario. The results of the fatigue load testing demonstrate that the subject devices are substantially equivalent to the predicate devices. Additionally, surface area and bone-to-implant contact (BIC) comparative analysis was performed in accordance with BioHorizons internally developed test protocol, followed by axial pullout testing in accordance with ASTM F543. Analysis compared the shortest length worst-case subject implants across both offered implant diameters to the shortest length worst-case primary predicate implants across equivalent implant diameters. Both evaluations demonstrated that the subject device provides increased external surface area, increased bone-to-implant contact and increased axial pullout strength as compared to the primary predicate device. Per FDA Guidance on "Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile," BioHorizons conducted baseline {5}------------------------------------------------ validation testing of representative worst-case BioHorizons endosseous dental implant devices using the Limulus Amebocyte Lysate (LAL) Method - Inhibition/Enhancement Assay (per USP Chapter <85>) for bacterial endotoxins. Testing demonstrated that EU/Device was less than 0.050 for all lots tested, which is below the established acceptance criteria of 20 EU/Device for medical devices not intended to contact cerebrospinal fluid. Sterilization validation was performed in accordance with ANSI/AAMI/ISO 11137-1. Validation testing was conducted on representative worst-case BioHorizons dental implant devices and demonstrates (1) that a minimum gamma radiation sterilization dose of 25kGy is substantiated for BioHorizons dental implant products, and (2) that BioHorizons dental implant products sterilized with a minimum 25 kGy gamma radiation dose may be released based on data from dosimeters without the need for sterility testing of each log. Shelf life testing was performed in accordance with applicable ASTM standards for evaluating seal strength of flexible barrier materials and porous medical packaging common to all BioHorizons sterile-packaged dental implants. Test results established the shelf life to be five years provided the sterile seal is not breached. The subject device is a titanium alloy, nonmechanical, non-active device, therefore, degradation in performance characteristics is not likely over the established shelf life period. Special storage conditions are not required for the device, as ambient storage conditions are not expected to adversely affect the safety or efficacy of the device. Additional data relied on from BioHorizons previous dental implant device submissions to demonstrate substantial equivalence to the predicate devices includes evaluation of the RBT surface treatment process as is applied to all BioHorizons dental implant devices. Evaluation included Scanning Electron Microscopy (SEM) at 100X, 1000X and 5000X demonstrating effective removal of all residual HA particulates, as well as Energy Dispersive X-Ray (EDX) spectroscopy demonstrating that there is no effect on the biocompatibility of the underlying titanium alloy material from RBT processing. Finally, BioHorizons Tapered Short Implants meet the chemical requirements of ASTM F136. This grade of Titanium is commonly used in surgical implant applications thus no special biocompatibility testing was conducted for the proposed devices. Historical biocompatibility testing conducted on representative BioHorizons dental implant devices that used the same ASTM F136 titanium alloy material that is used exclusively in the manufacture of all BioHorizons dental implant devices included cytotoxicity, irritation and sensitization testing. Test results concluded that the test articles were non-cytotoxic, non-irritating and negative for evidence of dermal sensitization under the test conditions employed. # Conclusion The data presented in this submission demonstrates that the proposed devices are substantially equivalent with respect to performance and intended use. The proposed devices perform as well as the legally marketed predicate devices. Furthermore, the proposed devices do not pose any new or increased risks as compared to the legally marketed predicate devices. {6}------------------------------------------------ | | Subject Device | Primary Predicate Device | Reference Predicate Devices | | | |----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | BioHorizons Implant Systems, Inc.<br>Tapered Short Implants<br>K172576 | BioHorizons Implant Systems, Inc.<br>Tapered Internal Plus Implants<br>K121787 | Biomet 3i<br>3i T3 Short Implants<br>K150571 | Bicon LLC<br>The Bicon 5.0 x 5.0mm and 6.0 x<br>5.0mm Dental Implant<br>K073368 | Bicon LLC<br>4.5 x 6.0mm and 6.0 x 6.0mm<br>Dental Implant<br>K050712 | | Intended Use | BioHorizons Tapered Short Implants are<br>intended for use in the mandible or<br>maxilla as an artificial root structure for<br>single tooth replacement or for fixed<br>bridgework and dental retention. The<br>implants may be restored using delayed<br>loading, or with a terminal or<br>intermediate abutment for fixed or<br>removable bridgework, and for<br>overdentures. | BioHorizons Tapered Internal Plus<br>Implants are intended for use in the<br>mandible or maxilla for use as an<br>artificial root structure for single tooth<br>replacement or for fixed bridgework and<br>dental retention.<br>BioHorizons Tapered Internal Plus<br>Implants may be restored immediately<br>1) with a temporary prosthesis that is<br>not in functional occlusion, or<br>2) when splinted together for multiple<br>tooth replacement, or when<br>stabilized with an overdenture<br>supported by multiple implants. | The 3i T3® Short Implants are<br>intended for surgical placement in the<br>upper or lower jaw to provide a means<br>for prosthetic attachment in single<br>tooth restorations and in partially or<br>fully edentulous spans with multiple<br>single teeth utilizing delayed loading,<br>or with a terminal or intermediary<br>abutment for fixed or removable<br>bridgework, and to retain<br>overdentures. | The 5.0 x 5.0mm and the 6.0 x 5.0mm<br>implants are designed as a one stage<br>or two stage surgical procedure<br>implant for use in edentulous sites in<br>the mandible or maxilla for support of<br>a complete denture prosthesis, a<br>terminal or intermediate abutment for<br>fixed bridgework, partial dentures, or a<br>single tooth replacement. | The 4.5 x 6.0mm and the 6.0 x<br>6.0mm implants are designed for use<br>in edentulous sites in the mandible or<br>maxilla for support of a complete<br>denture prosthesis, a terminal or<br>intermediate abutment for fixed<br>bridgework, partial dentures, or a<br>single tooth replacement. | | Design | | | | | | | Implant shape | Tapered | Tapered | Parallel wall | Parallel wall | Parallel wall | | Implant body diameter | 4.6mm, 5.8mm | 3.8mm, 4.6mm, 5.8mm | 5.0mm, 6.0mm | 5.0mm, 6.0mm | 4.5mm, 6.0mm | | Implant length | 6.0mm, 7.5mm | 7.5mm (except 3.8mm body), 9mm,<br>10.5mm, 12mm, 15mm | 5.0mm, 6.0mm | 5.0mm | 6.0mm | | Outer thread | Buttress | Buttress | V-thread | Fin design (tapped into place, not<br>screwed) | Fin design (tapped into place, not<br>screwed) | | Surface | Implant - RBT<br>Collar - Laser-Lok | Implant - RBT<br>Collar - Laser-Lok | T3 (blasted, acid etched) or<br>T3 DCD (blasted, acid etched and<br>calcium phosphate applied to surface) | Integra-Ti (grit blasted, acid etched) or<br>Integra-CP (hydroxylapatite surface) | Integra-Ti (grit blasted, acid etched)<br>or<br>Integra-CP (hydroxylapatite surface) | | Connection | Internal Hex | Internal Hex | Flat to flat butt joint | Tapered connection, non-indexing | Tapered connection, non-indexing | | Internal thread | Spiralock UNF 1-72 | Spiralock UNF 1-72 | Not known | Not known | Not known | | Prosthetic platform | 3.5mm, 4.5mm | 3.0mm, 3.5mm, 4.5mm | Not known | Not known | Not known | | Material and Manufacturing | | | | | | | Implant Material | Ti-6Al-4V (ASTM F136) | Ti-6Al-4V (ASTM F136) | Grade 4 pure titanium | Ti-6Al-4V | Ti-6Al-4V | | Manufacturing process | Machined by BioHorizons or A-level<br>supplier, surface treated with micro-<br>machined grooves (Laser-Lok) and RBT | Machined by BioHorizons or A-level<br>supplier, surface treated with micro-<br>machined grooves (Laser-Lok) and<br>RBT | Not known - proprietary | Not known - proprietary | Not known - proprietary | | Packaging | Tyvek-lidded blister tray (primary<br>package), placed inside a tamper-evident<br>outer box (secondary package) | Tyvek-lidded blister tray (primary<br>package), placed inside a tamper-<br>evident outer box (secondary package) | Not known | Not known | Not known | | Sterilization | 25-40 kGy gamma irradiation dose range | 25-40 kGy gamma irradiation dose<br>range | Not known | Not known | Not known | #### Table 1. Summary Table of Substantial Equivalence
Innolitics
510(k) Summary
Decision Summary
Classification Order
Enter a record ID and click Load to view the document.
100%